{"id":302,"date":"2017-12-14T15:14:39","date_gmt":"2017-12-14T20:14:39","guid":{"rendered":"http:\/\/www.myositis.org\/myositis-library\/published-research\/dermatomyositis-studies\/"},"modified":"2025-04-25T10:58:21","modified_gmt":"2025-04-25T14:58:21","slug":"dermatomyositis-and-polymyositis-studies","status":"publish","type":"page","link":"https:\/\/www.myositis.org\/myositis-library\/published-research\/dermatomyositis-and-polymyositis-studies\/","title":{"rendered":"Dermatomyositis and Polymyositis Studies"},"content":{"rendered":"<p><strong>The following list of published research is intended to serve as a resource for study of inflammatory myopathies.<\/strong><\/p>\n<h3>2025<\/h3>\n<p><strong>Lisa Christopher-Stine, Julie J. Paik, Alexandra S. Gouriounova, Paul N. Mudd.\u00a0<\/strong><a href=\"https:\/\/www.myositis.org\/wp-content\/uploads\/2025\/03\/2025-Patient_reported_physical_function_mental_health_a.pdf\" target=\"_blank\" rel=\"noopener\">Patient reported physical function, mental health, and treatment patterns in dermatomyositis: survey results from a cross-sectional study of adult dermatomyositis patients<\/a>.\u00a0<em>BMC Rheumatology\u00a0<\/em>(2025) 9:23<\/p>\n<h3>2024<\/h3>\n<p><strong>Lisa Christopher-Stine, Anna Ciesluk, Hector Chinoy, Namita A. Goyal, Kaniah Gunter, David Isenberg, Adrian Kielhorn, Ingrid E. Lundberg, Tahseen Mozaffar, Sanjay Rakhade, Gerrit Vandenberg, and Rohit Aggarwal.<\/strong> <a href=\"https:\/\/www.jrheum.org\/content\/jrheum\/51\/12\/1198.full.pdf\" target=\"_blank\" rel=\"noopener\">The Dermatomyositis Disease Symptom Questionnaire (DM-DSQ) &#8211; A Measure to Assess the Patient Experience of Dermatomyositis Symptoms<\/a>. <em>The Journal of Rheumatology, <\/em>2024;51:1198\u2013207. doi:10.3899\/jrheum.2023-1137<\/p>\n<h3><span style=\"color: #993300;\">2021<\/span><\/h3>\n<ul>\n<li><strong>Rohit Aggarwal, MDa, Christina Charles-Schoeman, MDb, Joachim Schessl, MDc, <\/strong><strong>Mazen M. Dimachkie, MDd, Irene Beckmanne, Todd Levine, MDf.\u00a0 <\/strong><a href=\"https:\/\/www.myositis.org\/wp-content\/uploads\/2021\/09\/ProDERM-Study-Protocol.pdf\" target=\"_blank\" rel=\"noopener\">ProDERM-Study-Protocolphase III study evaluating efficacy and safety of octagam 10% in patients with dermatomyositis (\u201cProDERM Study\u201d)<\/a>.\u00a0 Medicine (2021) 100:1.<\/li>\n<\/ul>\n<h3><span style=\"color: #993300;\">2020<\/span><\/h3>\n<ul>\n<li><strong>Parks CG, Wilkerson J, Rose KM, Faiq A, Farhadi PN, Long CS, MS, Bayat N, Brunner HI, Goldberg B, JA McGrath, Miller FW, and Rider LG.<\/strong> <a href=\"https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC7051886\/\">Association of Ultraviolet Radiation Exposure with Dermatomyositis in a National Myositis Patient Registry MYOVISION.<\/a> <em>Arthritis Care Res<\/em> (Hoboken). 2020 Nov; 72(11): 1636\u20131644. doi: 10.1002\/acr.24059.<\/li>\n<\/ul>\n<h3><span style=\"color: #993300;\">2019<\/span><\/h3>\n<ul>\n<li><strong>Christopher-Stine L, Kelly W, Wan G, Kobert L, Reed M.<\/strong> Polymyositis (PM) and Dermatomyositis (DM) symptom flares and associated impact from the patient perspective [abstract]. <em>Arthritis Rheumatol.<\/em> 2019; 71 (suppl 10).<\/li>\n<\/ul>\n<h3><span style=\"color: #993300;\">2018<\/span><\/h3>\n<ul>\n<li><strong>Labrador-Horrillo M and Selva-O\u2019Callaghan A<\/strong>. <a href=\"https:\/\/www.myositis.org\/wp-content\/uploads\/2018\/07\/Cancer-associated-Dermatomyositis-Does-the-PD-1-Checkpoint-Pathway-Play-a-Role-2018.pdf\" target=\"_blank\" rel=\"noopener\">Cancer-associated Dermatomyositis: Does the PD-1 checkpoint pathway play a role?<\/a> J Rheumatol 2018. 45(6);731-732.<\/li>\n<li><strong>Victoria P. Werth, David Pearson, Joyce Okawa, Rui Feng, Josef Concha, Basil Patel, Emily Hejazi, Caitlin Cornwall, Scott Constantine, Barbara White.<\/strong> <a href=\"https:\/\/www.myositis.org\/wp-content\/uploads\/2019\/01\/safety_and_efficacy_of_lenabasum_in_refractory_skin_predominant_dermatomyositis_subjects_treated_on_an_open_label_extension_of_trial_jbt101_dm_001-2018.pdf\" target=\"_blank\" rel=\"noopener\">Safety and efficacy of lenabasum in refractory skin-predominant dermatomyositis subjects treated on an open-label extension of trial JBT101-DM-001<\/a>. ACR\/ARHP Annual Meeting, October 23, 2018.<\/li>\n<li><strong>Nithin Reddy, Majid Zeidi, Barbara White, Victoria P. Werth.<\/strong> <a href=\"https:\/\/www.myositis.org\/wp-content\/uploads\/2019\/01\/lenabasum_a_cannabinoid_type_2_receptor_agonist_reduces_t_cell_population_and_downregulates_type_1_and_2_interferon_activities_in_lesional_dermatomyositis_skin-2018.pdf\" target=\"_blank\" rel=\"noopener\">Lenabasum, a cannabinoid type 2 receptor agonist, reduces T-cell population and downregulates type 1 and 2 interferon activities in lesional dermatomyositis skin<\/a>. ACR\/ARHP Annual Meeting, October 24, 2018.<\/li>\n<li><strong>Ayodeji Adegunsoye, Justin M. Oldham, Shashi K. Bellam, Jonathan H. Chung, Paul A. Chung, Kathleen M. Biblowitz, Steven Montner, Cathryn Lee, Scully Hsu, Aliya N. Husain, Rekha Vij, Gokhan Mutlu, Imre Noth, Matthew M. Churpek, Mary E. Strek.<\/strong> <a href=\"https:\/\/www.myositis.org\/wp-content\/uploads\/2019\/01\/African-American-race-and-mortality-in-ild-a-MULTICENTRE-PROPENSITY-MATCHED-ANALYSIS-2018.pdf\" target=\"_blank\" rel=\"noopener\">African-American race and mortality in interstitial lung disease: A multicentre propensity-matched analysis<\/a>. <em>Eur Respir J.<\/em> 2018 June; 51(6). doi:10.1183\/13993003.00255-2018.<\/li>\n<\/ul>\n<h3><span style=\"color: #993300;\">2017<\/span><\/h3>\n<ul>\n<li><strong>Edison K, Brod B<\/strong>. <a href=\"http:\/\/www.myositis.org\/wp-content\/uploads\/2018\/02\/PIIS0190962217300178.pdf\" target=\"_blank\" rel=\"noopener\"> Burden of skin disease report: Implications for dermatology<\/a>.\u00a0<em>J Am Acad Dermatol<\/em>. 2017.<\/li>\n<li><strong>Buckley, Lenore, Gordon Guyatt, Howard A. Fink, et al<\/strong>. <a href=\"http:\/\/www.myositis.org\/wp-content\/uploads\/2018\/02\/2017_ACR_Guideline_for_the_Prevention_and_Treatment_of_Glucocorticoid-Induced_Osteoporosis.pdf\" target=\"_blank\" rel=\"noopener\">American College of Rheumatology guidelines for the prevention and treatment of glucocorticoid-induced osteoporosis<\/a>.\u00a0<em>Arthritis &amp; Rheumatology<\/em>. 2017, 69(8): 2326-5205. doi. 10.1002\/art.40137.<\/li>\n<li><strong>Noem\u00ed De Luna, Xavier Su\u00e1rez-Calvet, Cinta Lleix\u00e0, Jordi Diaz-Manera, Montse Oliv\u00e9,\u00a0Isabel Illa, Eduard Gallardo<\/strong>. <a href=\"http:\/\/www.myositis.org\/wp-content\/uploads\/2018\/02\/Hypoxia_triggers_IFN-I_production_in_muscle_Implications_in_DM_2017_-_Suarez-Calvet.pdf\" target=\"_blank\" rel=\"noopener\">Hypoxia triggers IFN-I production in muscle: Implications in dermatomyositis<\/a>.\u00a0<em>Scientific Reports<\/em>. 2017, 7:8595. DOI 10.1038\/s41598-017-09309-8.<\/li>\n<li><strong>Xavier Su\u00e1rez-Calvet, Eduard Gallardo, Iago Pinal-Fernandez, Noemi De Luna, Cinta Lleix\u00e0,\u00a0Jordi D\u00edaz-Manera, Ricardo Rojas-Garc\u00eda, Ivan Castellv\u00ed, M. Angeles Mart\u00ednez, Josep M. Grau,\u00a0Albert Selva-O&#8217;Callaghan, Isabel Illa<\/strong>. <a href=\"http:\/\/www.myositis.org\/wp-content\/uploads\/2018\/02\/RIG-I_expression_in_perifascicular_myofibers_is_a_biomarker_DM_-_2017_-_Suarez-Calvet.pdf\" target=\"_blank\" rel=\"noopener\">RIG-I expression in perifascicular myofibers is a reliable biomarker of dermatomyositis<\/a>.\u00a0<em>Arthritis Research &amp; Therapy<\/em>. 2017, 19:174. DOI 10.1186\/s13075-017-1383-0.<\/li>\n<li><strong>Victoria P. Werth, Emily Hejazi, Sandra M. Pena, Jessica S. Haber, Joyce Okawa, Rui Feng, Kirubel Gabre, Josef Concha, Caitlin Cornwall, Nancy Dgetluck, Scott Constantine, Barbara White<\/strong>. <a href=\"http:\/\/www.myositis.org\/wp-content\/uploads\/2018\/02\/Phase_2_Study_of_Safety_and_Efficacy_of_Anabasum_JBT-101_-_ACR_Abstract_2017.pdf\" target=\"_blank\" rel=\"noopener\">A phase 2 study of safety and efficacy of anabasum (JBT-101), a cannabinoid receptor type 2 agonist, in refractory skin-predominant dermatomyositis<\/a>.\u00a0Abstract presented at ACR\/ARHP Annual Meeting, November 7, 2017.<\/li>\n<li><strong>Morrell TJ, Mortensen WS, Langley S<\/strong>. <a href=\"https:\/\/www.myositis.org\/wp-content\/uploads\/2018\/07\/Amyopathic-Dermatomyositis-With-Plantar-keratoderma-2017.pdf\" target=\"_blank\" rel=\"noopener\">Amyopathic dermatomyositis with plantar keratoderma responding to methotrexate therapy<\/a>. Cutis. 2017. 100(2); E20-E24.<\/li>\n<li><strong>Iago Pinal-Fernandez, Maria Casal-Dominguez, Julio A. Huapaya, Jemima Albayda, Julie J. Paik, Cheilonda Johnson, Leann Silhan, Lisa Christopher-Stine, Andrew L. Mammen, Sonye K. Danoff.<\/strong> <a href=\"https:\/\/www.myositis.org\/wp-content\/uploads\/2019\/01\/A-longitudinal-cohort-study-of-the-anti-synthetase-syndrome-increased-severity-of-interstitial-lung-disease-in-black-patients-and-patients-with-anti-PL7-and-anti-PL12-autoantibodies-201.pdf\" target=\"_blank\" rel=\"noopener\">A longitudinal cohort study of the anti-synthetase syndrome: Increased severity of interstitial lung disease in black patients and patients with anti-PL7 and anti-PL12 autoantibodies<\/a>. <em>Rheumatology<\/em> 2017;56:999-1007. doi:10.1093\/rheumatology\/kex02.<br \/>\n[TMA-funded research]<\/li>\n<li><strong>Michael C. Kwa, Kaveh Ardalan, Anne E. Laumann, Jonathan I. Silverberg.<\/strong> <a href=\"https:\/\/www.myositis.org\/wp-content\/uploads\/2019\/01\/Predictors-of-Hospitalization-Length-of-stay-and-cost-of-care-amg-adults-w-DM-in-US-2017.pdf\" target=\"_blank\" rel=\"noopener\">Predictors of hospitalization, length of stay, and cost of care among adults with dermatomyositis in the United States. Arthritis Care &amp; Research<\/a>. 2017; 69(9): 1391\u20131399. DOI 10.1002\/acr.23190.<\/li>\n<\/ul>\n<h3><span style=\"color: #993300;\">2016<\/span><\/h3>\n<ul>\n<li><strong>Andrew L. Mammen, MD, PhD,corresponding author Livia Casciola-Rosen, PhD, Lisa Christopher-Stine, MD, MPH, Thomas E. Lloyd, MD, PhD, and Kathryn R. Wagner, MD, PhD<\/strong>. \u00a0<a href=\"https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC4676353\/\" target=\"_blank\" rel=\"noopener\">Myositis-specific autoantibodies are specific for myositis compared to genetic muscle disease<\/a>. \u00a0<em>Neurology, Neuroimmunology &amp; Neuroinflammation<\/em>. \u00a02015 Dec; 2(6): e172. \u00a0Published online 2015 Nov 19. doi:\u00a0 0.1212\/NXI.0000000000000172.<\/li>\n<li><strong>Lorenzo Cavagna, MD, Laura Nu\u00f1o, MD, Carlo Alberto Scir\u00e8, MD, Marcello Govoni, MD, Francisco Javier Lopez Longo, MD, Franco Franceschini, MD, Rossella Neri, MD, Santos Casta\u00f1eda, MD, Walter Alberto Sifuentes Giraldo, MD, Roberto Caporali, MD, Florenzo Iannone, MD, Enrico Fusaro, MD, Giuseppe Paolazzi, MD, Raffaele Pellerito, MD, Andreas Schwarting, MD, Lesley Ann Saketkoo, MD, Norberto Ortego-Centeno, MD, Luca Quartuccio, MD, Elena Bartoloni, MD, Christof Specker, MD, Trinitario Pina Murcia, MD, Renato La Corte, MD, Federica Furini, MD, Valentina Foschi, MD, Javier Bachiller Corral, MD, Paolo Air\u00f2, MD, Ilaria Cavazzana, MD, Julia Mart\u00ednez-Barrio, MD, Michelle Hinojosa, MD, Margherita Giannini, MD, Simone Barsotti, MD, Julia Menke, MD, Kostantinos Triantafyllias, MD, Rosetta Vitetta, MD, Alessandra Russo, MD, Gianluigi Bajocchi, MD, Elena Bravi, MD, Giovanni Barausse, MD, Roberto Bortolotti, MD, Carlo Selmi, MD, Simone Parisi, MD, Carlomaurizio Montecucco, MD, and Miguel Angel Gonz\u00e1lez-Gay, MD, on Behalf of AENEAS (American, European NEtwork of Antisynthetase Syndrome) collaborative group<\/strong>. \u00a0<a href=\"https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC4616698\/#!po=70.0000\" target=\"_blank\" rel=\"noopener\">Clinical Spectrum Time Course in Anti Jo-1 Positive Antisynthetase Syndrome<\/a>. \u00a0<em>Medicine<\/em> (Baltimore). 2015 Aug; 94(32): e1144. \u00a0Published online 2015 Aug 14. doi: 10.1097\/MD.0000000000001144.<\/li>\n<li><strong>E.S. Robinson, R. Feng,J. Okawa,and V.P. Werth<\/strong>. \u00a0<a href=\"https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC4333145\/\" target=\"_blank\" rel=\"noopener\">Improvement in the cutaneous disease activity of patients with dermatomyositis is associated with a better quality of life<\/a>. \u00a0<em>NCBI Resources<\/em>. \u00a0Br J Dermatol. Author manuscript; available in PMC 2016 Jan 1. \u00a0Published in final edited form as: \u00a0Br J Dermatol. 2015 Jan; 172(1): 169\u2013174. \u00a0Published online 2014 Nov 30. doi: 10.1111\/bjd.13167 \u00a0PMCID: PMC4333145 \u00a0NIHMSID: NIHMS603151.<\/li>\n<li><strong>Kari Oakes<\/strong>.\u00a0<a href=\"https:\/\/www.mdedge.com\/familypracticenews\/article\/114636\/lupus-connective-tissue-diseases\/be-alert-dermatomyositis-without\" target=\"_blank\" rel=\"noopener\">Be alert for dermatomyositis without muscle disease<\/a>.\u00a0<em>Family Practice News<\/em>. 2016, Sept. 28.<\/li>\n<li><strong>Aggarwal R, Oddis CV, Goudeau D, Koontz D, Qi Z, Reed AM, Ascherman DP, Levesque MC<\/strong>.\u00a0<a href=\"https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/26888854\" target=\"_blank\" rel=\"noopener\">Autoantibody levels in myositis patients correlate with clinical response during B cell depletion with rituximab<\/a>.\u00a0<em>Rheumatology<\/em>\u00a0(Oxford). 2016 Jun; 55(6):991-9. doi: 10.1093\/rheumatology\/kev444. Epub 2016 Feb 16.<\/li>\n<li><strong>Allenbach Y, Leroux G, Su\u00e1rez-Calvet X, Preusse C, Gallardo E, Hervier B, Rigolet A, Hie M, Pehl D, Limal N, Hufnagl P, Zerbe N, Meyer A, Aouizerate J, Uzunhan Y, Maisonobe T, Goebel H-H, Benveniste O, Stenzel W, and the French Myositis Network<\/strong>. <a href=\"http:\/\/www.myositis.org\/wp-content\/uploads\/2018\/02\/Dermatomyositis_With_or_Without_anti_mda5_Ab_-_2016_-_Suarez-Calvet.pdf\" target=\"_blank\" rel=\"noopener\">Dermatomyositis with or without anti-melanoma differentiation-associated gene 5 antibodies<\/a>.\u00a0<em>The American Journal of Pathology<\/em>. 2016;186(3).<\/li>\n<li><strong>Y. Allenbach, G. Leroux, X. Su\u00e1rez-Calvet, C. Preusse, E. Gallardo, B, Hervier, A, Rigolet, M. Hie, D. Pehl, N. Limal, P. Hufnagl, N. Zerbe, A. Meyer, J. Aouizerate, Y. Uzunhan, T. Maisonobe, H.H. Goebel, O. Benveniste, W. Stenzel, and the French Myositis Network<\/strong>. <a href=\"http:\/\/www.myositis.org\/wp-content\/uploads\/2018\/02\/5-Dermatomyositis_With_or_Without_anti_mda5_Ab_-_2016_-_Suarez-Calvet-1.pdf\" target=\"_blank\" rel=\"noopener\">Dermatomyositis with or without anti-melanoma differentiation-associated gene 5 antibodies common interferon signature but distinct NOS2 expression<\/a>.\u00a0<em>American Journal of Pathology<\/em>, 2016, 186(3). DOI: 10.1016\/j.ajpath.2015.11.010.<\/li>\n<li><strong>Shu X, Peng Q, Lu X, Wang G<\/strong>. <a href=\"http:\/\/www.myositis.org\/wp-content\/uploads\/2018\/02\/HMGB1_May_Be_a_Biomarker_for_Predicting_2016.pdf\" target=\"_blank\" rel=\"noopener\">HMGB1 may be a biomarker for predicting the outcome in patients with polymyositis\/dermatomyositis with interstitial lung disease<\/a>.\u00a0<em>PLoS\u00a0ONE<\/em>. 2016, 11(8): e0161436. doi:10.1371\/journal.pone.0161436<\/li>\n<li><strong>Ingela Loell, Joan Raouf, Yi-Wen Chen, Rongye Shi, Inger Nennesmo, Helene Alexanderson, Maryam Dastmalchi, Kanneboyina Nagaraju, Marina Korotkova, Ingrid E. Lundberg<\/strong>. <a href=\"http:\/\/www.myositis.org\/wp-content\/uploads\/2018\/02\/Effects_on_muscle_tissue_remodeling_and_lipid_metabolism_in_muscle_tissue_from_PM___DM_treated_with_immunosuppression_2017.pdf\" target=\"_blank\" rel=\"noopener\">Effects on muscle tissue remodeling and lipid metabolism in muscle tissue from adult patients with polymyositis or dermatomyositis treated with immunosuppressive agents<\/a>.\u00a0<em>Arthritis Research &amp; Therapy<\/em>. 2016, 18:136. DOI 10.1186\/s13075-016-1033-y.<\/li>\n<\/ul>\n<p><strong><span style=\"color: #993300;\">2015<\/span><\/strong><\/p>\n<ul>\n<li><strong>Fowzia Ibrahim, Ernest Choy, Patrick Gordon, Caroline J. Dor\u00e9, Alan Hakim, George Kitas, David Isenberg, Bridget Griffiths, Bryan Lecky, Kuntal Chakravarty, John Winer, Katalin Danko, Robert G. Cooper, Beverley White-Alao and David L. Scott<\/strong>.\u00a0\u00a0S<a href=\"https:\/\/academic.oup.com\/rheumatology\/article\/54\/6\/1050\/1799716\" target=\"_blank\" rel=\"noopener\">econd-line agents in myositis: 1-year factorial trial of additional immunosuppression in patients who have partially responded to steroids<\/a>.\u00a0\u00a0The British Society for Rheumatology Biologics Register. \u00a0<em>Rheumatology<\/em> (2014) doi: 10.1093\/rheumatology\/keu442.<\/li>\n<li><strong>Thorsten Hornung, M.D., Viktor Janzen, M.D., Franz-Josef Heidgen, M.D., Dominik Wolf, M.D., Thomas Bieber, M.D., Ph.D. and Joerg Wenzel, M.D.<\/strong> \u00a0<a href=\"http:\/\/www.nejm.org\/doi\/full\/10.1056\/NEJMc1412997\" target=\"_blank\" rel=\"noopener\">Remission of Recalcitrant Dermatomyositis Treated with Ruxolitinib<\/a>.\u00a0\u00a0<em>The New England Journal of Medicine<\/em>. \u00a0N Engl J Med 2014; 371:2537-2538December 25, 2014DOI: 10.1056\/NEJMc1412997.<\/li>\n<li><strong>Lenka Ple\u0161tilov\u00e1, He\u0159man Mann, Lucie Andr\u00e9s Cerezo1, Ond\u0159ej Pecha, Ji\u0159\u00ed Vencovsk\u00fd and Ladislav \u0160enol<\/strong>t.\u00a0\u00a0<a href=\"https:\/\/arthritis-research.biomedcentral.com\/articles\/10.1186\/s13075-014-0468-2\" target=\"_blank\" rel=\"noopener\">The metastasis promoting protein S100A4 levels associate with disease activity rather than cancer development in patients with idiopathic inflammatory myopathies<\/a>.\u00a0\u00a0<em>Arthritis Research &amp; Therapy<\/em> 2014, 16:468 doi:10.1186\/s13075-014-0468-2.<\/li>\n<li><strong>Han Wang, Yingying Cai, Lin Cai, Yingchun Hu, Xianxiang Chen, Juelin Deng<\/strong>.\u00a0<a href=\"https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC3933648\/pdf\/pone.0089827.pdf\" target=\"_blank\" rel=\"noopener\">Altered Lipid Levels in Untreated Patients with Early Polymyositis<\/a>.\u00a0\u00a0<em>PLOS ONE<\/em> <a href=\"http:\/\/www.plosone.org\">www.plosone.org<\/a> 1 February 2014 | Volume 9 | Issue 2 |.<\/li>\n<li><strong>Tobias Ruck, Stefan Bittner, Tanja Kuhlmann, Heinz Wiendl, and Sven G. Meuth<\/strong>.\u00a0\u00a0<a href=\"https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC4334687\/\" target=\"_blank\" rel=\"noopener\">Long-term efficacy of alemtuzumab in polymyositis<\/a>.\u00a0\u00a0<em>Rheumatology<\/em> (Oxford). 2015 Mar; 54(3): 560\u2013562.\u00a0 Published online 2014 Dec 30. doi: 10.1093\/rheumatology\/keu484.<\/li>\n<li><strong>Eleni Linos, David Fiorentino, Bharathi Lingala, Eswar Krishnan and Lorinda Chung<\/strong>.\u00a0<a href=\"https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC3672763\/\" target=\"_blank\" rel=\"noopener\">Atherosclerotic cardiovascular disease and dermatomyositis: an analysis of the Nationwide Inpatient Sample survey<\/a>.\u00a0\u00a0<em>Arthritis Res Ther<\/em>. 2013; 15(1): R7.\u00a0 Published online 2013 Jan 8. doi: 10.1186\/ar4135.<\/li>\n<li><strong>Takashi Kurita, Shinsuke Yasuda, Koji Oba, Toshio Odani, Michihito Kono, Kotaro Otomo, Yuichiro Fujieda, Kenji Oku, Toshiyuki Bohgaki, Olga Amengual, Tetsuya Horita and Tatsuya Atsumi<\/strong>. \u00a0<a href=\"https:\/\/academic.oup.com\/rheumatology\/article\/54\/1\/39\/1837931\" target=\"_blank\" rel=\"noopener\">The efficacy of tacrolimus in patients with interstitial lung diseases complicated with polymyositis or dermatomyositis<\/a>. \u00a0<em>Rheumatology<\/em>\u00a0(2015) 54 (1): 39-44. \u00a0doi: 10.1093\/rheumatology\/keu166. \u00a0First published online: April 24, 2014<\/li>\n<li><strong>Ann M. Reed, corresponding author Cynthia S. Crowson, Molly Hein, Consuelo Lopez de Padilla, Jeannette M. Olazagasti, Rohit Aggarwal, Dana P. Ascherman, Marc C. Levesque, Chester V. Oddis, and the RIM Study Group<\/strong>. \u00a0<a href=\"https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC4574570\/\" target=\"_blank\" rel=\"noopener\">Biologic predictors of clinical improvement in rituximab-treated refractory myositis<\/a>. \u00a0<em>BMC Musculoskelet Disord<\/em>. 2015; 16: 257. Published online 2015 Sep 17. doi: 10.1186\/s12891-015-0710-3.<\/li>\n<li><strong>Samuel Katsuyuki Shinjoand Fernando Henrique Carlos de Souza<\/strong>. \u00a0<a href=\"http:\/\/www.scielo.br\/scielo.php?pid=S0482-50042013000200009&amp;script=sci_arttext&amp;tlng=en\">Update on the treatment of calcinosis in dermatomyositis<\/a>. \u00a0<em>Scielo<\/em>. \u00a0Print version ISSN 0482-5004\u00a0Rev. Bras. Reumatol. vol.53 no.2 S\u00e3o Paulo Mar.\/Apr. 2013\u00a0http:\/\/dx.doi.org\/10.1590\/S0482-50042013000200009.<\/li>\n<\/ul>\n<h3><span style=\"color: #993300;\">2014<\/span><\/h3>\n<ul>\n<li><strong>Luciena Cegatto Martins Ortigosa and Vitor Manuel Silva dos Reis<\/strong>. \u00a0<a href=\"https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC4155949\/\" target=\"_blank\" rel=\"noopener\">A review of DM cases in Brazil<\/a>.\u00a0\u00a0<em>An Bras Dermatol<\/em>. 2014 Sep-Oct; 89(5): 719\u2013727.\u00a0 doi: 10.1590\/abd1806-4841.20143422<\/li>\n<li><strong>Moises Labrador-Horrillo, Maria Angeles Martinez, Albert Selva-O&#8217;Callaghan, Ernesto Trallero-Araguas, Eva Balada, Miquel Vilardell-Tarresand and C\u00e1ndido Ju\u00e1rez<\/strong>.\u00a0\u00a0<a href=\"https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC3987881\/\" target=\"_blank\" rel=\"noopener\">Anti-MDA5 antibodies in dermatomyositis<\/a>. \u00a0<em>J Immunol Res<\/em>. 2014; 2014: 290797.\u00a0 Published online Feb 4, 2014. doi: 10.1155\/2014\/290797<\/li>\n<li><strong>Tu, Jenny; McLean-Tooke, Andrew; Junckerstorff, Reimar<\/strong>.\u00a0\u00a0<a href=\"https:\/\/escholarship.org\/uc\/item\/1599r51x\" target=\"_blank\" rel=\"noopener\">Dermatomyositis with swelling<\/a>.\u00a0\u00a0<em>Dermatology Online Journal<\/em>.\u00a0<a href=\"http:\/\/escholarship.org\/uc\/item\/1599r51x\" target=\"_blank\" rel=\"noopener\">http:\/\/escholarship.org\/uc\/item\/1599r51x<\/a>.<\/li>\n<li><strong>Alexandra Maria Giovanna Brunasso, Werner Aberer and Cesare Massone<\/strong>.\u00a0\u00a0<a href=\"https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC3926249\/\" target=\"_blank\" rel=\"noopener\">New Onset of Dermatomyositis\/Polymyositis during Anti-TNF-\u03b1 Therapies: A Systematic Literature Review<\/a>. \u00a0<em>ScientificWorldJournal<\/em>. 2014; 2014: 179180.\u00a0 Published online Jan 29, 2014. doi: 10.1155\/2014\/179180<\/li>\n<li><strong>Melina Andrade Mattar, Bruno Gualano, Luiz Augusto Perandini, Samuel Katsuyuki Shinjo, Fernanda Rodrigues Lima, Ana L\u00facia S\u00e1-Pinto, and Hamilton Roschelcorresponding<\/strong>.\u00a0\u00a0<a href=\"https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC4232679\/\" target=\"_blank\" rel=\"noopener\">Safety and possible effects of low-intensity resistance training associated with partial blood flow restriction in polymyositis and dermatomyositis<\/a>.\u00a0\u00a0<em>Arthritis Res Ther<\/em>. 2014; 16(5): 473.\u00a0 Published online Oct 25, 2014. doi: 10.1186\/s13075-014-0473-5<\/li>\n<li><strong>Aggarwal R, Bandos A, Reed AM, Ascherman DP, Barohn RJ, Feldman BM, Miller FW, Rider LG, Harris-Love MO, Levesque MC, the RIM Study Group, Oddis CV<\/strong>. <a href=\"http:\/\/www.myositis.org\/wp-content\/uploads\/2018\/02\/Predictors_of_Clinical_Improvement_in_Rituximab-treated_refractory_DM__PM_2014.pdf\" target=\"_blank\" rel=\"noopener\">Predictors of Clinical Improvement in Rituximab-Treated Refractory Adult and Juvenile Dermatomyositis and Adult Polymyositis<\/a>.\u00a0<em>Arthritis &amp; Rheumatology<\/em>\u00a02014;66:740\u2013749. DOI 10.1002\/art.38270.<\/li>\n<li><strong>C. Johnson, G.R. Connors, J. Oaks, S. Han, A. Truong, B. Richardson, N. Lechtzin, A.L. Mammen, L. Casciola-Rosen, L. Christopher-Stine, S.K. Danoff.\u00a0<\/strong> <a href=\"https:\/\/www.myositis.org\/wp-content\/uploads\/2019\/01\/Clinical-and-pathologic-differences-inILD-based-on-ASynA-type-2014.pdf\" target=\"_blank\" rel=\"noopener\">Clinical and pathologic differences in interstitial lung disease based on antisynthetase antibody type<\/a>. <em>Respiratory Medicine<\/em> 2014; 108: 1542-1548. DOI: 10.1016\/j.rmed.2014.09.003.<\/li>\n<\/ul>\n<h3><span style=\"color: #993300;\">2013<\/span><\/h3>\n<ul>\n<li><strong>Marie I, Hatron PY, Dominique S, Cherin P, Mouthon L, Menard JF<\/strong>.\u00a0\u00a0<a href=\"https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/21702020\" target=\"_blank\" rel=\"noopener\">Short-term and long-term outcomes of interstitial lung disease in polymyositis and dermatomyositis:\u00a0 a series of 107 patients<\/a>.\u00a0\u00a0<a href=\"http:\/\/www.nbci.nlm.nih.gov\/pubmed\/21702020\" target=\"_blank\" rel=\"noopener\">http:\/\/www.nbci.nlm.nih.gov\/pubmed\/21702020<\/a>.<\/li>\n<li><strong>Chester V. Oddis, Ann M. Reed, Rohit Aggarwal, Lisa G. Rider, Dana P. Ascherman, Marc C. Levesque, Richard J. Barohn, Brian M. Feldman, Michael O. Harris-Love, Diane C. Koontz, Noreen Fertig, Stephanie S. Kelley, Sherrie L. Pryber, Frederick W. Miller, Howard E. Rockette, and the RIM Study Group<\/strong>.\u00a0 <a href=\"http:\/\/www.myositis.org\/wp-content\/uploads\/2018\/02\/Oddis_Rtx__in_tx_of_Myositis_RIM_Study_with_Editorial_2013.pdf\" target=\"_blank\" rel=\"noopener\"> Rituzimab in the Treatment of Refractory Adult and Juvenile Dermatomyositis and Adult Polymyositis<\/a>.\u00a0\u00a0<em>Arthritis &amp; Rheumatism<\/em>.\u00a0 Vol. 65, No. 2, February 2013, pp 314-324 DOI 10.1002\/art.37754<\/li>\n<li><strong>Angela Ceribelli, Micaela Fredi, Mara Taraborelli, Ilaria Cavazzana, Franco Franeschini, Marzia Quinzanini, Angela Tincani, Steven J Ross, Jason YF Chan, Brad Pauley, Edward KL Chan and Minoru Satoh<\/strong>.\u00a0 <a href=\"http:\/\/www.myositis.org\/wp-content\/uploads\/2018\/02\/ar3822.pdf\" target=\"_blank\" rel=\"noopener\">Anti-MJ\/NXP-2 autoantibody specificity in a cohort of adult Italian patients with polymyositis\/dermatomyositis<\/a>.\u00a0\u00a0<em>Arthritis Research and Therapy<\/em>.\u00a0 Ceribelli et al. Arthritis Research &amp; Therapy 2012, 14:R97.\u00a0\u00a0<a href=\"http:\/\/arthritis-research.com\/content\/14\/2\/R97\" target=\"_blank\" rel=\"noopener\">http:\/\/arthritis-research.com\/content\/14\/2\/R97<\/a>.<\/li>\n<li><strong>Zhang Lu, MD; Wang Guo-chun, PhD; Ma Li, BS; Zu Ning, PhD<\/strong>.\u00a0\u00a0<a href=\"https:\/\/www.dropbox.com\/s\/b8ra38ai30txk5k\/22026_ftp.pdf\" target=\"_blank\" rel=\"noopener\">Cardiac Involvement in Adult Polymyositis or Dermatomyositis:\u00a0 A Systematic Review<\/a>.\u00a0\u00a0<em>Clinical Investigations<\/em>.<\/li>\n<li><strong>Kei Kunimasa, Machiko Arita, Takashi Nakazawa, Maki Tanaka, Kazuya Tsubouchi, Satoshi Konishi, Yasushi Fukuda, Mika Saigusa, Hiroaki Nakagawa, Satoshi Ubukata, Yohei Korogi, Takao Fujii, Tsuneyo Mimori and Tadashi Ishida<\/strong>.\u00a0 <a href=\"http:\/\/www.myositis.org\/wp-content\/uploads\/2018\/02\/51_51.7452.pdf\" target=\"_blank\" rel=\"noopener\">The Clinical Characteristics of Two Anti-OJ (Anti-IsoleucyltRNA Synthetase) Autoantibody-Positive Interstitial Lung Disease Patients with Polymyositis\/Dermatomyositis<\/a>.\u00a0\u00a0<em>Internal Medicine<\/em>.\u00a0 DOI:\u00a0 10.2169\/internalmedicine.51.7425.<\/li>\n<li><strong>Nicole P Sandhu, Shaheen Zakaria, Amy C Degnim, Judy C Boughey<\/strong>.\u00a0 <a href=\"http:\/\/www.myositis.org\/wp-content\/uploads\/2018\/02\/bcr.10.2010.3416.pdf\" target=\"_blank\" rel=\"noopener\">Dermatomyositis presenting as a paraneoplasic syndrome due to underlying breast cancer<\/a>.\u00a0\u00a0<em>BMJ Case Reports\u00a0<\/em>2011;10.1136\/bcr.10.2010.3416.<\/li>\n<li><strong>Fernando Henrique Carlos de SouzaI, Thiago Bitar Moraes BarrosII, Maur\u00edcio Levy-NetoI II, Samuel Katsuyuki Shinjo IV<\/strong>.\u00a0 <a href=\"http:\/\/www.scielo.br\/scielo.php?script=sci_arttext&amp;pid=S0482-50042012000600008&amp;lng=en&amp;nrm=iso&amp;tlng=en\" target=\"_blank\" rel=\"noopener\">Adult dermatomyositis: experience of a Brazilian tertiary care center<\/a>.\u00a0<em>Revista Brasileira de Reumatologia<\/em>.\u00a0 Print version ISSN 0482-5004 Rev. Bras. Reumatol. vol.52 no.6 S\u00e3o Paulo Nov.\/Dec. 2012\u00a0\u00a0http:\/\/dx.doi.org\/10.1590\/S0482-50042012000600008.\u00a0Portuguese Version<\/li>\n<li><strong>Nicolas Prevel, Yves Allenbach, David Klatzmann, Benoit Salomon, and Olivier Benveniste<\/strong>.\u00a0<a href=\"https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC3827074\/\" target=\"_blank\" rel=\"noopener\">Beneficial role of rapamycin in experimental autoimmune myositis<\/a>. <em>PLoS One<\/em>. 2013; 8(11): e74450. doi:\u00a010.1371\/journal.pone.0074450<\/li>\n<\/ul>\n<h3><span style=\"color: #993300;\">2012<\/span><\/h3>\n<ul>\n<li><strong>Todd Levine<\/strong>.\u00a0 <a href=\"http:\/\/www.myositis.org\/wp-content\/uploads\/2018\/02\/Levine_paper.pdf\" target=\"_blank\" rel=\"noopener\">Treating refractory dermatomyositis or polymyositis with adrenocorticotropic hormone gel: a restrospective case series<\/a> .\u00a0\u00a0<em>Drug Design, Development and Therapy<\/em>\u00a02012:6\u00a0 133-139<\/li>\n<li><strong>Tahseen Mozaffar &amp; Alan Pestronk<\/strong>.\u00a0 <a href=\"http:\/\/www.myositis.org\/wp-content\/uploads\/2018\/02\/472.full_.pdf\" target=\"_blank\" rel=\"noopener\">Myopathy with anti-Ko-1 antibodies: pathology in perimysium and neighbouring muscle fibres<\/a>.\u00a0\u00a0<em>J Neurol Neurosurg Psychiatry<\/em>\u00a02000; 68:\u00a0 472-478.<\/li>\n<li><strong>Elena Schiopu, Kristine Phillips, Paul M MacDonald, Leslie Crofford and Emily Somers<\/strong>.\u00a0\u00a0<a href=\"https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC3392815\/\" target=\"_blank\" rel=\"noopener\">Predictors of survival in a cohort of patients with polymyositis and dermatomyositis:\u00a0 effects of corticosteriods, methotrexate and azathioprine<\/a>.\u00a0 <em>Arthrithis Research Ther<\/em>.\u00a0 Published online 2012 January 21.\u00a0 doi:\u00a0 10.1186\/ar3704.<\/li>\n<\/ul>\n<h3><span style=\"color: #993300;\">2011<\/span><\/h3>\n<ul>\n<li><strong>Michael Benatar, MD<\/strong>. <a href=\"http:\/\/www.myositis.org\/wp-content\/uploads\/2018\/02\/Etanercept_trial.pdf\" target=\"_blank\" rel=\"noopener\">Dermatomyositis-Etanercept Trial<\/a>.\u00a0<em>Journal Watch Neurology<\/em>. October 4, 2011.<\/li>\n<li><strong>Solomon J, Swigris JJ, Brown KK<\/strong>. <a href=\"http:\/\/www.myositis.org\/wp-content\/uploads\/2018\/02\/ILD_and_antisynthetase_syndrome_2011.pdf\" target=\"_blank\" rel=\"noopener\">Myositis-related interstitial lung disease and antisynthetase syndrome<\/a>.\u00a0<em>J Bras Pneumol<\/em>. 2011 February ; 37(1): 100\u2013109.<\/li>\n<\/ul>\n<h3><span style=\"color: #993300;\">2010<\/span><\/h3>\n<ul>\n<li><strong>E.C. Ebert<\/strong>. <a href=\"http:\/\/www.myositis.org\/wp-content\/uploads\/2018\/02\/Gastrointestinal_Ebert.pdf\" target=\"_blank\" rel=\"noopener\">Gastrointestinal Ebert<\/a>.\u00a0<em>Alimentary Pharmacology &amp; Therapeutics<\/em> 31, 359-365.<\/li>\n<li><strong>Andrew L. Mammen<\/strong>.\u00a0 <a href=\"http:\/\/www.myositis.org\/wp-content\/uploads\/2018\/02\/Mammen_NYAS_DM_and_PM_review_2010_-_published_version.pdf\" target=\"_blank\" rel=\"noopener\"> Dermatomyositis and polymyositis Clinical presentation, autoantibodies, and pathogenesis<\/a>. <em>New York Academy of Sciences<\/em>. Ann. N.Y. Acad. Sci. 1184 (2010) 134-153.<\/li>\n<li><strong>Andrew L. Mammen, Livia A. Casciola-Rosen, John C. Hall, Lisa Christopher-Stine, Andrea M. Corse, and Anthony Rosen<\/strong>. <a href=\"http:\/\/www.myositis.org\/wp-content\/uploads\/2018\/02\/1-Mammen_NYAS_DM_and_PM_review_2010_-_published_version-1.pdf\" target=\"_blank\" rel=\"noopener\"> Expression of the Dermatomyositis Autoantigen Mi-2 in Regenerating Muscle<\/a>.\u00a0<em>Arthritis &amp; Rheumatism<\/em>. Col. 60, No. 12, December 2009, pp 3784-3793. DOI 10.1002\/art.24977.<\/li>\n<li><strong>Jennie T. Clarke and Victoria P. Werth<\/strong>.\u00a0 <a href=\"http:\/\/www.myositis.org\/wp-content\/uploads\/2018\/02\/Rheumatic_manifestations_of_skin_disease.14.pdf\" target=\"_blank\" rel=\"noopener\">Rheumatic manifestations of skin disease<\/a>.\u00a0Current Opinion in <em>Rheumatology<\/em>. 2010, 22:78-84. DOI:10.1097\/BOR.0b013e328333b9e2.<\/li>\n<\/ul>\n<h3><span style=\"color: #993300;\">2009<\/span><\/h3>\n<ul>\n<li><strong>Rider, Lachenbruch, Monroe, Ravelli, Cabalar, Feldman, Villalba, Myones, Pachman, Rennebohm, Reed and Miller for the IMACS Groups<\/strong>. <a href=\"http:\/\/www.myositis.org\/wp-content\/uploads\/2018\/02\/Damage_Extent_and_Predictors.pdf\" target=\"_blank\" rel=\"noopener\">Damage Extent and Predictors in Adult Juvenile Dermatomyositis and Polymyositis as determined with the myositis damage index<\/a>.\u00a0<em>Arthritis &amp; Rheumatism<\/em>; vol. 60, No. 11, November 2009, pp 3425-3435. DOI 10.1002\/art.24904.<\/li>\n<li><strong>Annaliese Tisseverasinghe, Sasha Bernatsky, Christian A. Pineau<\/strong>.\u00a0 <a href=\"http:\/\/www.myositis.org\/wp-content\/uploads\/2018\/02\/cardio_pm_dm.pdf\" target=\"_blank\" rel=\"noopener\">Cardio PM\/DM<\/a>.\u00a0<em>The Journal of Rheumatology<\/em> 2009: 36:9; doi: 10.3899\/jrheum.090061.<\/li>\n<\/ul>\n<h3><span style=\"color: #993300;\">2006 &#8211; 2007<\/span><\/h3>\n<ul>\n<li><strong>Callen JP, Wortmann RL<\/strong>.\u00a0 <a href=\"http:\/\/www.myositis.org\/wp-content\/uploads\/2018\/02\/Dermatomyositis_by_Callen_and_Wortmann.pdf\" target=\"_blank\" rel=\"noopener\">Dermatomyositis<\/a> .\u00a0<em>Clinics in Dermatology<\/em>. 2006;24:363-73.<\/li>\n<li><strong>Yuen-Li C, Alexanderson H, Pipitone N, Morrison C, Dastmalchi M, Stahl-Hallengren C, et al<\/strong>.\u00a0 <a href=\"http:\/\/www.myositis.org\/wp-content\/uploads\/2018\/02\/Alexanderson2007.pdf\" target=\"_blank\" rel=\"noopener\"> Creatine supplements in patients with idiopathic inflammatory myopthies who are clinically weak after conventional pharmacologic treatment: six-month, double-blind, randomized, placebo-controlled trial<\/a>.\u00a0<em>Arthritis &amp; Rheumatism<\/em>. 2007 May 15;57(4):694-702.<\/li>\n<li><strong>Danya S, Werth VP<\/strong>.\u00a0 <a href=\"http:\/\/www.myositis.org\/wp-content\/uploads\/2018\/02\/DMrash_treatment_with_antiestrogen.pdf\" target=\"_blank\" rel=\"noopener\"> Improvement of dermatomyositis rash associated with the use of antiestrogen medication<\/a>.\u00a0<em>Archives of Dermatology<\/em>. 2006;142:70-2.<\/li>\n<li><strong>Edge JC, Outland JD, Dempsey JR, Callen JP<\/strong>.\u00a0 <a href=\"http:\/\/www.myositis.org\/wp-content\/uploads\/2018\/02\/Mycophenolate__as_Effective_Corticosteroid.pdf\" target=\"_blank\" rel=\"noopener\"> Mycophenolate mofetil as an effective corticosteroid-sparing therapy for recalcitrant dermatomyositis<\/a>.\u00a0<em>Archives of Dermatology<\/em>. 2006;142:65-9.<\/li>\n<\/ul>\n<h3><span style=\"color: #993300;\">2001 &#8211; 2005<\/span><\/h3>\n<ul>\n<li><strong>Danieli MG, et al<\/strong>.\u00a0<a href=\"https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/11779756?ordinalpos=18&amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum\" target=\"_blank\" rel=\"noopener\">Cyclosporin A and intravenous immunoglobulin treatment in polymyositis\/dermatomyositis<\/a>.\u00a0<em>Ann Rheum\u00a0Dis<\/em> 61: 37-41, 2002<\/li>\n<li><strong>Cherin P, et al<\/strong>.\u00a0<a href=\"https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/11840450?ordinalpos=1&amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum\" target=\"_blank\" rel=\"noopener\">Results and long-term followup of intravenous immunoglobulin infusions in chronic, refractory polymyositis<\/a>.\u00a0<em>Arthritis Rheum<\/em>\u00a046 (2): 467-474, 2002<\/li>\n<li><strong>Marie M, et al<\/strong>.\u00a0<a href=\"https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/11669162?ordinalpos=1&amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum\" target=\"_blank\" rel=\"noopener\">Polymyositis and dermatomyositis: Short term and longterm outcome, and predictive factors of prognosis<\/a>.\u00a0<em>J Rheumatol<\/em> 28: 2230-7, 2001<\/li>\n<\/ul>\n<h3><span style=\"color: #993300;\">1996 &#8211; 2000<\/span><\/h3>\n<ul>\n<li><strong>Villalba L, et al<\/strong>.\u00a0<a href=\"https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/9506565?ordinalpos=1&amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum\" target=\"_blank\" rel=\"noopener\">Treatment of refractory myositis. A randomized crossover study of two new cytotoxic regimens<\/a>.\u00a0<em>Arthritis Rheum<\/em>\u00a041 (3): 392-399, 1998<\/li>\n<li><strong>Adams EM, et al<\/strong>.\u00a0<a href=\"https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/9972969?ordinalpos=1&amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum\" target=\"_blank\" rel=\"noopener\">A pilot study: Use of fludarabine for refractory dermatomyositis and polymyositis, and examination of endpoint measures<\/a>. <em>J\u00a0Rheumatol<\/em>\u00a026: 352-360, 1999.<\/li>\n<li><strong>Vencovsky J, et al<\/strong>.\u00a0<a href=\"https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/10777122?ordinalpos=1&amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum\" target=\"_blank\" rel=\"noopener\">Cyclosporine A versus methotrexate in the treatment of polymyositis and dermatomyositis<\/a>.\u00a0Scand <em>J Rheumatol<\/em>\u00a029: 95-102, 2000<\/li>\n<\/ul>\n<h3><span style=\"color: #993300;\">1991 &#8211; 1995<\/span><\/h3>\n<ul>\n<li><strong>Cherin P, et al<\/strong>.\u00a0<a href=\"https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/1714235?ordinalpos=1&amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum\" target=\"_blank\" rel=\"noopener\">Efficacy of intravenous gammaglobulin therapy in chronic refractory polymyositis and dermatomyositis: An open study with 20 adult patients<\/a>.\u00a0<em>Am J Med<\/em>\u00a091: 162-168, 1991<\/li>\n<li><strong>Miller FW, et al<\/strong>.\u00a0<a href=\"https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/1472183?ordinalpos=1&amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum\" target=\"_blank\" rel=\"noopener\">Controlled trial of plasma exchange and leukapheresis in polymyositis and dermatomyositis<\/a>.\u00a0<em>N Engl J Med<\/em>\u00a0326: 1380-1384, 1992<\/li>\n<li><strong>Dalakas MC, et al<\/strong>.\u00a0<a href=\"https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/8247075?ordinalpos=2&amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum\" target=\"_blank\" rel=\"noopener\">A controlled trial of high-dose intravenous immune globulin infusions as treatment for dermatomyositis<\/a>.\u00a0<em>N Engl J Med<\/em>: 329: 1993-2000, 1993<\/li>\n<li><strong>Cherin P, et al<\/strong>.\u00a0<a href=\"https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/7932419?ordinalpos=1&amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum\" target=\"_blank\" rel=\"noopener\">Intravenous gamma globulin as first line therapy in polymyositis and dermatomyositis: An open study in 11 adult patients<\/a>.\u00a0<em>J Rheumatol<\/em> 21: 1092-1097, 1994<\/li>\n<\/ul>\n","protected":false},"excerpt":{"rendered":"<p>The following list of published research is intended to serve as a resource for study of inflammatory myopathies. 2025 Lisa Christopher-Stine, Julie J. Paik, Alexandra S. Gouriounova, Paul N. Mudd.\u00a0Patient&#8230;<\/p>\n","protected":false},"author":189,"featured_media":0,"parent":299,"menu_order":314,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_acf_changed":false,"_monsterinsights_skip_tracking":false,"_monsterinsights_sitenote_active":false,"_monsterinsights_sitenote_note":"","_monsterinsights_sitenote_category":0,"footnotes":""},"class_list":["post-302","page","type-page","status-publish","hentry"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v26.1.1 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Dermatomyositis and Polymyositis Studies - The Myositis Association<\/title>\n<meta name=\"description\" content=\"See a list of published research relating to dermatomyositis and polymyositis. Click each study title to read the full study.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.myositis.org\/myositis-library\/published-research\/dermatomyositis-and-polymyositis-studies\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Dermatomyositis and Polymyositis Studies - The Myositis Association\" \/>\n<meta property=\"og:description\" content=\"See a list of published research relating to dermatomyositis and polymyositis. Click each study title to read the full study.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.myositis.org\/myositis-library\/published-research\/dermatomyositis-and-polymyositis-studies\/\" \/>\n<meta property=\"og:site_name\" content=\"The Myositis Association\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/Myositis\/\" \/>\n<meta property=\"article:modified_time\" content=\"2025-04-25T14:58:21+00:00\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:site\" content=\"@themyositisassc\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"13 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.myositis.org\/myositis-library\/published-research\/dermatomyositis-and-polymyositis-studies\/\",\"url\":\"https:\/\/www.myositis.org\/myositis-library\/published-research\/dermatomyositis-and-polymyositis-studies\/\",\"name\":\"Dermatomyositis and Polymyositis Studies - The Myositis Association\",\"isPartOf\":{\"@id\":\"https:\/\/www.myositis.org\/#website\"},\"datePublished\":\"2017-12-14T20:14:39+00:00\",\"dateModified\":\"2025-04-25T14:58:21+00:00\",\"description\":\"See a list of published research relating to dermatomyositis and polymyositis. Click each study title to read the full study.\",\"breadcrumb\":{\"@id\":\"https:\/\/www.myositis.org\/myositis-library\/published-research\/dermatomyositis-and-polymyositis-studies\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.myositis.org\/myositis-library\/published-research\/dermatomyositis-and-polymyositis-studies\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.myositis.org\/myositis-library\/published-research\/dermatomyositis-and-polymyositis-studies\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/www.myositis.org\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Myositis Library\",\"item\":\"https:\/\/www.myositis.org\/myositis-library\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Published Research\",\"item\":\"https:\/\/www.myositis.org\/myositis-library\/published-research\/\"},{\"@type\":\"ListItem\",\"position\":4,\"name\":\"Dermatomyositis and Polymyositis Studies\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.myositis.org\/#website\",\"url\":\"https:\/\/www.myositis.org\/\",\"name\":\"The Myositis Association\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\/\/www.myositis.org\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.myositis.org\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.myositis.org\/#organization\",\"name\":\"The Myositis Association\",\"url\":\"https:\/\/www.myositis.org\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.myositis.org\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/www.myositis.org\/wp-content\/uploads\/2017\/12\/site-icon.png\",\"contentUrl\":\"https:\/\/www.myositis.org\/wp-content\/uploads\/2017\/12\/site-icon.png\",\"width\":\"512\",\"height\":\"512\",\"caption\":\"The Myositis Association\"},\"image\":{\"@id\":\"https:\/\/www.myositis.org\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/Myositis\/\",\"https:\/\/x.com\/themyositisassc\",\"https:\/\/www.youtube.com\/user\/MyositisAssociation\"]}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Dermatomyositis and Polymyositis Studies - The Myositis Association","description":"See a list of published research relating to dermatomyositis and polymyositis. Click each study title to read the full study.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.myositis.org\/myositis-library\/published-research\/dermatomyositis-and-polymyositis-studies\/","og_locale":"en_US","og_type":"article","og_title":"Dermatomyositis and Polymyositis Studies - The Myositis Association","og_description":"See a list of published research relating to dermatomyositis and polymyositis. Click each study title to read the full study.","og_url":"https:\/\/www.myositis.org\/myositis-library\/published-research\/dermatomyositis-and-polymyositis-studies\/","og_site_name":"The Myositis Association","article_publisher":"https:\/\/www.facebook.com\/Myositis\/","article_modified_time":"2025-04-25T14:58:21+00:00","twitter_card":"summary_large_image","twitter_site":"@themyositisassc","twitter_misc":{"Est. reading time":"13 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.myositis.org\/myositis-library\/published-research\/dermatomyositis-and-polymyositis-studies\/","url":"https:\/\/www.myositis.org\/myositis-library\/published-research\/dermatomyositis-and-polymyositis-studies\/","name":"Dermatomyositis and Polymyositis Studies - The Myositis Association","isPartOf":{"@id":"https:\/\/www.myositis.org\/#website"},"datePublished":"2017-12-14T20:14:39+00:00","dateModified":"2025-04-25T14:58:21+00:00","description":"See a list of published research relating to dermatomyositis and polymyositis. Click each study title to read the full study.","breadcrumb":{"@id":"https:\/\/www.myositis.org\/myositis-library\/published-research\/dermatomyositis-and-polymyositis-studies\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.myositis.org\/myositis-library\/published-research\/dermatomyositis-and-polymyositis-studies\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.myositis.org\/myositis-library\/published-research\/dermatomyositis-and-polymyositis-studies\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.myositis.org\/"},{"@type":"ListItem","position":2,"name":"Myositis Library","item":"https:\/\/www.myositis.org\/myositis-library\/"},{"@type":"ListItem","position":3,"name":"Published Research","item":"https:\/\/www.myositis.org\/myositis-library\/published-research\/"},{"@type":"ListItem","position":4,"name":"Dermatomyositis and Polymyositis Studies"}]},{"@type":"WebSite","@id":"https:\/\/www.myositis.org\/#website","url":"https:\/\/www.myositis.org\/","name":"The Myositis Association","description":"","publisher":{"@id":"https:\/\/www.myositis.org\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.myositis.org\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/www.myositis.org\/#organization","name":"The Myositis Association","url":"https:\/\/www.myositis.org\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.myositis.org\/#\/schema\/logo\/image\/","url":"https:\/\/www.myositis.org\/wp-content\/uploads\/2017\/12\/site-icon.png","contentUrl":"https:\/\/www.myositis.org\/wp-content\/uploads\/2017\/12\/site-icon.png","width":"512","height":"512","caption":"The Myositis Association"},"image":{"@id":"https:\/\/www.myositis.org\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/Myositis\/","https:\/\/x.com\/themyositisassc","https:\/\/www.youtube.com\/user\/MyositisAssociation"]}]}},"_links":{"self":[{"href":"https:\/\/www.myositis.org\/wp-json\/wp\/v2\/pages\/302","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.myositis.org\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/www.myositis.org\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/www.myositis.org\/wp-json\/wp\/v2\/users\/189"}],"replies":[{"embeddable":true,"href":"https:\/\/www.myositis.org\/wp-json\/wp\/v2\/comments?post=302"}],"version-history":[{"count":3,"href":"https:\/\/www.myositis.org\/wp-json\/wp\/v2\/pages\/302\/revisions"}],"predecessor-version":[{"id":22852,"href":"https:\/\/www.myositis.org\/wp-json\/wp\/v2\/pages\/302\/revisions\/22852"}],"up":[{"embeddable":true,"href":"https:\/\/www.myositis.org\/wp-json\/wp\/v2\/pages\/299"}],"wp:attachment":[{"href":"https:\/\/www.myositis.org\/wp-json\/wp\/v2\/media?parent=302"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}